CREB inhibits AP-2α expression to regulate the malignant phenotype of melanoma

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Melnikova, Vladislava O ^a   Dobroff, Andrey S ^a   Zigler, Maya ^a   Villares, Gabriel J ^a   Braeuer, Russell R ^a   Wang, Hua ^a   Huang, Li ^a   Bar Eli, Menashe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD146 ANTIGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 2ALPHA; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1A; E2F1 PROTEIN, HUMAN; MCAM PROTEIN, HUMAN; TRANSCRIPTION FACTOR AP 2;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MELANOMA; METASTASIS POTENTIAL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; UPREGULATION; ANIMAL; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD146; CELL LINE, TUMOR; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; NEOPLASM METASTASIS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 77957892438     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012452     Document Type: Article

References (70)

1. Sharpless NE, Kannan K, Xu J, Bosenberg MW, Chin L (2003) Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene 22: 5055-5059.
2. Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID, et al. (1998) Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2α, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 22: 157-163.
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
4. Zhang J, Williams T (2003) Identification and regulation of tissue-specific cisacting elements associated with the human AP-2α gene. Dev Dyn 228: 194-207.
5. Schorle H, Meier P, Buchert M, Jaenisch R, Mitchell PJ (1996) Transcription factor AP-2 essential for cranial closure and craniofacial development. Nature 381: 235-238.
6. Poser I, Bosserhoff AK (2004) Transcription factors involved in development and progression of malignant melanoma. Histol Histopathol 19: 173-188.
7. Dobroff AS, Wang H, Melnikova VO, Villares GJ, Zigler M, et al. (2009) Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma. J Biol Chem 284: 26194-26206.
8. Melnikova VO, Bar-Eli M (2008) Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther 7: 997-1003.
9. Bhoumik A, Ronai Z (2008) ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities. Cell Cycle 7: 2341-2345.
10. Tellez C, McCarty M, Ruiz M, Bar-Eli M (2003) Loss of activator protein- 2αlpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem 278: 46632-46642.
11. Tellez CS, Davis DW, Prieto VG, Gershenwald JE, Johnson MM, et al. (2007) Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2αlpha and protease-activated receptor-1 expression during melanoma progression. J Invest Dermatol 127: 387-393.
12. Jean D, Gershenwald JE, Huang S, Luca M, Hudson MJ, et al. (1998) Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 273: 16501-16508.
13. Miller AJ, Mihm MC, Jr. (2006) Melanoma. N Engl J Med 355: 51-65.
14. Gershenwald JE, Sumner W, Calderone T, Wang Z, Huang S, et al. (2001) Dominant-negative transcription factor AP-2 augments SB2 melanoma tumor growth in vivo. Oncogene 20: 3363-3375.
15. Bar-Eli M (1999) Role of AP-2 in tumor growth and metastasis of human melanoma. Cancer Metastasis Rev 18: 377-385.
16. Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, et al. (2005) Automated quantitative analysis of activator protein-2αlpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res 65: 11185-11192.
17. Zeng YX, Somasundaram K, el-Deiry WS (1997) AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet 15: 78-82.
18. McPherson LA, Loktev AV, Weigel RJ (2002) Tumor suppressor activity of AP2αlpha mediated through a direct interaction with p53. J Biol Chem 277: 45028-45033.
19. Wajapeyee N, Somasundaram K (2003) Cell cycle arrest and apoptosis induction by activator protein 2α (AP-2α) and the role of p53 and p21WAF1/ CIP1 in AP-2α-mediated growth inhibition. J Biol Chem 278: 52093-52101.
20. Huang S, Jean D, Luca M, Tainsky MA, Bar-Eli M (1998) Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. Embo J 17: 4358-4369.
21. Schwartz B, Melnikova VO, Tellez C, Mourad-Zeidan A, Blehm K, et al. (2007) Loss of AP-2α results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo. Oncogene 26: 4049-4058.
22. Jonckheere N, Fauquette V, Stechly L, Saint-Laurent N, Aubert S, et al. (2009) Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2α overexpression. Br J Cancer 101: 637-644.
23. Cowley GP, Smith ME (1996) Cadherin expression in melanocytic naevi and malignant melanomas. J Pathol 179: 183-187.
24. Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, et al. (1996) The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci U S A 93: 9160-9165.
25. Natali PG, Nicotra MR, Digiesi G, Cavaliere R, Bigotti A, et al. (1994) Expression of gp185HER-2 in human cutaneous melanoma: implications for experimental immunotherapeutics. Int J Cancer 56: 341-346.
26. Descheemaeker KA, Wyns S, Nelles L, Auwerx J, Ny T, et al. (1992) Interaction of AP-1-, AP-2-, and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response. J Biol Chem 267: 15086-15091.
27. van den Oord JJ, Vandeghinste N, De Ley M, De Wolf-Peeters C (1994) Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 145: 294-300.
28. Gille J, Swerlick RA, Caughman SW (1997) Transforming growth factor-alphainduced transcriptional activation of the vascular permeability factor (VPF/ VEGF) gene requires AP-2-dependent DNA binding and transactivation. Embo J 16: 750-759.
29. Silins G, Grimmond S, Egerton M, Hayward N (1997) Analysis of the promoter region of the human VEGF-related factor gene. Biochem Biophys Res Commun 230: 413-418.
30. Werner H, Stannard B, Bach MA, LeRoith D, Roberts CT, Jr. (1990) Cloning and characterization of the proximal promoter region of the rat insulin-like growth factor I (IGF-I) receptor gene. Biochem Biophys Res Commun 169: 1021-1027.
31. Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, et al. (2005) Loss of the AP-2α transcription factor is associated with the grade of human gliomas. Clin Cancer Res 11: 267-272.
32. Nyormoi O, Bar-Eli M (2003) Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis 20: 251-263.
33. Leslie MC, Bar-Eli M (2005) Regulation of gene expression in melanoma: new approaches for treatment. J Cell Biochem 94: 25-38.
34. Mayr B, Montminy M (2001) Transcriptional regulation by the phosphorylation- dependent factor CREB. Nat Rev Mol Cell Biol 2: 599-609.
35. Ravnskjaer K, Kester H, Liu Y, Zhang X, Lee D, et al. (2007) Cooperative interactions between CBP and TORC2 confer selectivity to CREB target gene expression. Embo J 26: 2880-2889.
36. Shaywitz AJ, Greenberg ME (1999) CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68: 821-861.
37. Melnikova VO, Mourad-Zeidan AA, Lev DC, Bar-Eli M (2006) Plateletactivating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem 281: 2911-2922.
38. White PC, Shore AM, Clement M, McLaren J, Soeiro I, et al. (2006) Regulation of cyclin D2 and the cyclin D2 promoter by protein kinase A and CREB in lymphocytes. Oncogene 25: 2170-2180.
39. Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, et al. (2005) Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci U S A 102: 4459-4464.
40. Xie S, Price JE, Luca M, Jean D, Ronai Z, et al. (1997) Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene 15: 2069-2075.
41. Jean D, Bar-Eli M (2000) Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family. Mol Cell Biochem 212: 19-28.
42. Jean D, Bar-Eli M (2001) Targeting the ATF-1/CREB transcription factors by single chain Fv fragment in human melanoma: potential modality for cancer therapy. Crit Rev Immunol 21: 275-286.
43. Melnikova VO, Balasubramanian K, Villares GJ, Dobroff AS, Zigler M, et al. (2009) Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. J Biol Chem 284: 28845-28855.
44. McGary EC, Lev DC, Bar-Eli M (2002) Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 1: 459-465.
45. Melnikova VO, Bar-Eli M (2006) Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res 19: 395-405.
46. Villares GJ, Dobroff AS, Wang H, Zigler M, Melnikova VO, et al. (2009) Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43. Cancer Res 69: 6730-6737.
47. Copeman MC (1992) The putative melanoma tumor-suppressor gene on human chromosome 6q. Pathology 24: 307-309.
48. Pathak S, Drwinga HL, Hsu TC (1983) Involvement of chromosome 6 in rearrangements in human malignant melanoma cell lines. Cytogenet Cell Genet 36: 573-579.
49. Zhang J, Cui P, Glatfelter AA, Cummings LM, Meltzer PS, et al. (1995) Microdissection based cloning of a translocation breakpoint in a human malignant melanoma. Cancer Res 55: 4640-4645.
50. Walker GJ, Palmer JM, Walters MK, Hayward NK (1995) A genetic model of melanoma tumorigenesis based on allelic losses. Genes Chromosomes Cancer 12: 134-141.
51. Miele ME, Robertson G, Lee JH, Coleman A, McGary CT, et al. (1996) Metastasis suppressed, but tumorigenicity and local invasiveness unaffected, in the human melanoma cell line MelJuSo after introduction of human chromosomes 1 or 6. Mol Carcinog 15: 284-299.
52. Trent JM, Stanbridge EJ, McBride HL, Meese EU, Casey G, et al. (1990) Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science 247: 568-571.
53. Welch DR, Chen P, Miele ME, McGary CT, Bower JM, et al. (1994) Microcellmediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. Oncogene 9: 255-262.
54. Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, et al. (2003) Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 63: 8103-8107.
55. Bar-Eli M (2001) Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res 14: 78-85.
56. Bauer R, Imhof A, Pscherer A, Kopp H, Moser M, et al. (1994) The genomic structure of the human AP-2 transcription factor. Nucleic Acids Res 22: 1413-1420.
57. Stevaux O, Dyson NJ (2002) A revised picture of the E2F transcriptional network and RB function. Curr Opin Cell Biol 14: 684-691.
58. Stevens C, La Thangue NB (2003) E2F and cell cycle control: a double-edged sword. Arch Biochem Biophys 412: 157-169.
59. Trimarchi JM, Lees JA (2002) Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 3: 11-20.
60. Bell LA, Ryan KM (2004) Life and death decisions by E2F-1. Cell Death Differ 11: 137-142.
61. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG, Jr., et al. (1996) E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 85: 549-561.
62. Wu L, Timmers C, Maiti B, Saavedra HI, Sang L, et al. (2001) The E2F1-3 transcription factors are essential for cellular proliferation. Nature 414: 457-462.
63. Harbour JW, Dean DC (2000) The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 14: 2393-2409.
64. Xie Y, Yin Y, Li L, Ma Y, Xiao Q (2009) Short interfering RNA directed against the E2F-1 gene suppressing gastric cancer progression in vitro. Oncol Rep 21: 1345-1353.
65. Gee JM, Robertson JF, Ellis IO, Nicholson RI, Hurst HC (1999) Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol 189: 514-520.
66. Ropponen KM, Kellokoski JK, Lipponen PK, Pietilainen T, Eskelinen MJ, et al. (1999) p22/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis. Br J Cancer 81: 133-140.
67. Li L, Price JE, Fan D, Zhang RD, Bucana CD, et al. (1989) Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites. J Natl Cancer Inst 81: 1406-1412.
68. Verschraegen CF, Giovanella BC, Mendoza JT, Kozielski AJ, Stehlin JS, Jr. (1991) Specific organ metastases of human melanoma cells injected into the arterial circulation of nude mice. Anticancer Res 11: 529-535.
69. Albino AP, Lloyd KO, Houghton AN, Oettgen HF, Old LJ (1981) Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med 154: 1764-1778.
70. Welch DR, Bisi JE, Miller BE, Conaway D, Seftor EA, et al. (1991) Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int J Cancer 47: 227-237.